Engineering lymphocyte subsets: tools, trials and tribulations
about
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemiaA transposon and transposase system for human applicationChimeric Antigen Receptors Modified T-Cells for Cancer TherapyCARs in chronic lymphocytic leukemia -- ready to driveRecombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyondImmune reconstitution in chronic lymphocytic leukemiaImmunotherapy for primary brain tumors: no longer a matter of privilegeGene therapy on the moveChimeric antigen receptor therapy for cancerImmunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapiesChimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trialsSleeping beauty system to redirect T-cell specificity for human applications.Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemiaFracture healing is accelerated in the absence of the adaptive immune system.Computational models of HIV-1 resistance to gene therapy elucidate therapy design principlesIFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells.CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.Gene Therapy 2017: Progress and Future Directions.Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Overview of cellular immunotherapy for patients with glioblastoma.Antigen-specific Th9 cells exhibit uniqueness in their kinetics of cytokine production and short retention at the inflammatory site.The battle over mTOR: an emerging theatre in host-pathogen immunityTargeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.A non-human primate model for analysis of safety, persistence, and function of adoptively transferred T cells.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Genetic modification of T cellsEngraftment of human central memory-derived effector CD8+ T cells in immunodeficient miceImmunotherapy for ovarian cancer: what's next?Stem cell-based anti-HIV gene therapy.Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancerCD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.Adoptive T cell therapy of cancer.Thymic T-cell development in allogeneic stem cell transplantationActivation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytesIL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.Transfer of mRNA Encoding Invariant NKT Cell Receptors Imparts Glycolipid Specific Responses to T Cells and γδT CellsSuperior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors
P2860
Q24594920-97E035B4-35B8-461C-A4B5-A7876378C032Q24630047-D13AF0B5-E49D-4EB8-80C7-76CDCDB295CFQ26773309-00EB0748-AFF7-4A9A-8E16-40F9C519572BQ26830526-C555F269-7DA0-49CB-9B7C-E6985031BB35Q26861563-1C47C3BE-A622-4EEF-9D9C-9F77FF0309C8Q26865561-FE8523F7-AB84-40D3-8D11-B0A2B8E49223Q27002510-B75E6BE6-9964-45C3-8721-02AA5F91ACBEQ27007012-A1B0B5EB-C1F6-411F-9375-56D9247E7C90Q27013599-3F011210-FC04-4787-BF3C-13FA94D852EFQ27027243-D09A7A8F-6DB9-4178-A198-6F1B30533E05Q27312288-B6A8DEE6-06B3-4F94-AA96-51EA88852AB6Q30535187-3C760A14-1351-41B2-9FB6-9F603FDBE5A3Q33564364-5B1FAA14-7060-4B16-ACD3-BB2B9907B628Q33635563-8BD59B83-0077-4E2E-A136-D2299A3E6C32Q33658642-0B7A08D9-9D73-46E9-B873-A716E01E9C6AQ33761188-DE81B272-A320-4192-8404-AD3C1BD2D4EAQ33867018-8218274F-C082-441B-94B5-45A7BD5BF878Q33886716-7FBD0149-14F0-4D4A-9A24-AB5ACFCC14BFQ33891559-B840D792-08C1-4CF7-9CBD-10BFB513118DQ34046041-C3725BC5-B3C7-4834-A4A2-206B83298F4EQ34122292-14CBAA03-3600-4D83-9881-2349985A8F8DQ34189694-CE62AA01-68FE-42E2-88FF-47FE7B1B78C2Q34332508-6B3D1DAB-2FD7-48C1-910E-DEF3506917F0Q34426431-98EE07B5-0660-44CF-9C4F-5A665D4BC882Q34473451-5CC7245A-EB24-4AC1-8E5A-BDC80DE4ED26Q34621730-6F169D2C-66F6-47FE-97E8-9903BB6697E0Q34625160-366EDB3C-471C-41C9-B6DF-17B6944ED430Q34625543-A7B6B290-742B-413C-AD32-5D34BE93120CQ34644876-5B5C9A12-4A0F-4CD1-BC20-9C43036771E5Q34667739-3AF07D5E-8EA6-4D08-AFBC-A653DCFE1463Q34743514-DB038C2A-F10A-4254-8DC0-127BC80147C5Q34769333-F4DF772A-42E0-44D1-A789-667CCD4C1B6EQ34777479-B125AD28-6DBD-4BA4-835F-AF444AAFBC7AQ34876434-27F95563-B729-4F37-93E9-3C43070B5E95Q34977470-30C8E82E-E912-425C-AEA0-7C7E88233EB7Q35083246-198262EC-7AD0-4E6A-AE4B-328E410709F1Q35522878-7E4A7F8D-EFD4-4837-A0D9-02B08ED0508EQ35578622-F86F55E2-DF1F-4F8A-B8EB-58D3A0EB04C0Q35677421-07E0C744-038A-4996-8D75-D40D387594ACQ35868868-A787081E-623E-44CC-B672-68C1523FFF3F
P2860
Engineering lymphocyte subsets: tools, trials and tribulations
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Engineering lymphocyte subsets: tools, trials and tribulations
@ast
Engineering lymphocyte subsets: tools, trials and tribulations
@en
type
label
Engineering lymphocyte subsets: tools, trials and tribulations
@ast
Engineering lymphocyte subsets: tools, trials and tribulations
@en
prefLabel
Engineering lymphocyte subsets: tools, trials and tribulations
@ast
Engineering lymphocyte subsets: tools, trials and tribulations
@en
P2860
P356
P1476
Engineering lymphocyte subsets: tools, trials and tribulations
@en
P2093
Carl H June
James L Riley
P2860
P304
P356
10.1038/NRI2635
P577
2009-10-01T00:00:00Z